Compares two ways of guiding heart ablation for atrial fibrillation
Tests heart-wall thickness scans to guide ablation in people with paroxysmal atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Thickness Map-Guided vs. Empirical PV Isolation Using Pulsed Field Ablation for Paroxysmal AF
Key facts
- Where
- Seoul, South KoreaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 19 and 80 years old?
Source: NCT07068646, who can take part
Where in South Korea
- Severance hospitalSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yonsei University
- Trial code
- NCT07068646
- Record updated
- 16 July 2025
- Original description
This is a prospective, multicenter, randomized controlled trial comparing CT-guided versus empirical pulsed field ablation (PFA) for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. The study investigates whether atrial wall thickness-based energy titration improves arrhythmia outcomes compared to standard empirical ablation using the PulseSelect™ system.Read full original descriptionShow less
Computed Tomogram Myocardial Thickness Map-Guided Pulmonary Vein Isolation vs. Empirical Pulmonary Vein Isolation in Pulse-Field Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF III)
This is a prospective, multicenter, randomized controlled trial comparing CT-guided versus empirical pulsed field ablation (PFA) for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. The study investigates whether atrial wall thickness-based energy titration improves arrhythmia outcomes compared to standard empirical ablation using the PulseSelect™ system.
Exclusion: Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs; Drug addicts or alcoholics; Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected; Patients with severe renal impairment or CT imaging difficulty using contrast media; Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery; Patients with active internal bleeding; Patients with a severe comorbid disease; Patients with persistent or permanent atrial fibrillation; Patients with valvular atrial fibrillation (mitral stenosis >grade 2, mechanical valve, mitral valvuloplasty); Expected survival < 1 year; Patients who cannot read the consent form (illiterates, foreigners, etc.); Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study.
Patient with paroxysmal atrial fibrillation who is scheduled for ablation procedure and ≥19 and ≤80 years of age; Left atrium size < 50mm; paroxysmal atrial fibrillation that is recurrence during antiarrhythmic drug treatment or is not able to use an antiarrhythmic drug; Patient who is indicated for anticoagulation therapy (for prevention of cerebral infarction).